CN114848684A - Composite probiotic composition with obvious effect of improving hyperlipidemia - Google Patents

Composite probiotic composition with obvious effect of improving hyperlipidemia Download PDF

Info

Publication number
CN114848684A
CN114848684A CN202210301358.2A CN202210301358A CN114848684A CN 114848684 A CN114848684 A CN 114848684A CN 202210301358 A CN202210301358 A CN 202210301358A CN 114848684 A CN114848684 A CN 114848684A
Authority
CN
China
Prior art keywords
food
probiotic composition
blood
lactobacillus
probio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210301358.2A
Other languages
Chinese (zh)
Inventor
其木格苏都
马杰
郭霄
刘晓军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inner Mongolia Ketuo Biology Co ltd
Original Assignee
Inner Mongolia Ketuo Biology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inner Mongolia Ketuo Biology Co ltd filed Critical Inner Mongolia Ketuo Biology Co ltd
Priority to CN202210301358.2A priority Critical patent/CN114848684A/en
Publication of CN114848684A publication Critical patent/CN114848684A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
    • A23C9/1307—Milk products or derivatives; Fruit or vegetable juices; Sugars, sugar alcohols, sweeteners; Oligosaccharides; Organic acids or salts thereof or acidifying agents; Flavours, dyes or pigments; Inert or aerosol gases; Carbonation methods
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
    • A23L11/50—Fermented pulses or legumes; Fermentation of pulses or legumes based on the addition of microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/065—Microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/125—Casei
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/169—Plantarum
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/175—Rhamnosus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/515—Animalis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/531—Lactis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Agronomy & Crop Science (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention provides a composite probiotic composition with obvious effect of improving hyperlipidemia, which comprises the following components: lactobacillus casei zhang (lactobacillus casei zhang); bifidobacterium animalis subsp. lactis V9(Bifidobacterium animalis subsp. lactis V9); lactobacillus plantarum P-8(Lactobacillus plantarum P-8); lactobacillus rhamnosus Probio-M9(Lactobacillus rhamnous Probio-M9) and Bifidobacterium lactis Probio-M8(Bifidobacterium lactis Probio-M8); the composite probiotic composition has the effects of preventing, relieving, assisting in treating or treating hyperlipidemia, and has a great application prospect in preparing products for relieving and treating hyperlipidemia and other diseases.

Description

Composite probiotic composition with obvious effect of improving hyperlipidemia
Technical Field
The invention relates to the technical field of probiotics, in particular to a composite probiotic composition with an obvious effect of improving hyperlipidemia.
Background
Hyperlipidemia (hyperlipoproteinemia), also known as hyperlipoproteinemia (hyperlipoproteinemia), refers to the condition that several lipid levels in plasma are higher than normal during the fat metabolism, and is mainly characterized by higher serum cholesterol (TC), Triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) than normal. Epidemiological and clinical medicine studies have shown that higher than normal levels of blood cholesterol are positively correlated with the occurrence of cardiovascular disease (CVD). It has been reported that 1mmol/L (>5.2mmol/L) higher than normal cholesterol level increases the risk of coronary heart disease by 35%, and that lowering the serum cholesterol level by 1% can lower the risk of cardiovascular and cerebrovascular disease by 2% to 3%. The main cause of cardiovascular disease is atherosclerosis, one of the risk factors for atherosclerosis being hypercholesterolemia.
Probiotics (probiotic) are generally defined as a group of active microorganisms that are capable of regulating and improving the intestinal flora and that have a promoting effect on human health when ingested in sufficient amounts from the diet. Probiotics are generally divided into three groups: lactic acid bacteria, bifidobacteria and others. Criteria for specifying a symbiotic strain as a probiotic include non-pathogenicity, human origin, tolerance to acids and bile salts, ability to colonize and survive in the gut, production of antibacterial substances and immunomodulatory activity. Many documents report and confirm that probiotics have the physiological functions of resisting tumors, resisting cancers and mutations, reducing blood pressure, maintaining the integrity of intestinal tracts and the like. In addition, the probiotics also has the function of reducing blood fat, and the function is highly concerned by related researchers at home and abroad.
Disclosure of Invention
Therefore, the technical problem to be solved by the invention is to provide the application of the composite probiotic composition in preparing food or medicines for preventing, relieving, assisting in treating or treating hyperlipidemia.
Therefore, the invention provides the following technical scheme:
use of a complex probiotic composition in the manufacture of a food product or medicament for the prevention, alleviation, co-treatment or treatment of hyperlipidaemia, said complex probiotic composition comprising:
lactobacillus casei Zhang (Lactobacillus casei Zhang) with the preservation number of CGMCC No. 5469;
bifidobacterium animalis subsp. lactis V9(Bifidobacterium animalis subsp. lactis V9) with the preservation number of CGMCC No. 5470;
lactobacillus plantarum P-8(Lactobacillus plantarum P-8), with the preservation number of CGMCC No. 6312;
lactobacillus rhamnosus Probio-M9(Lactobacillus rhamnous Probio-M9) with the preservation number of CGMCC No. 18639; and
bifidobacterium lactis Probio-M8(Bifidobacterium lactis Probio-M8) with the collection number of CGMCC No. 18610.
Optionally, the total viable count of the composite probiotic composition is not less than 3.0 × 10 10 cfu/g, viable count of each strain is not less than 6.0 × 10 9 cfu/g。
Optionally, the raw material of each strain comprises any one of a culture, a fermentation product or freeze-dried powder of the strain;
optionally, the raw material of each strain is freeze-dried powder of the strain.
Optionally, the coating also comprises auxiliary materials;
optionally, the auxiliary material is prebiotics or dietary fibers;
optionally, the auxiliary material comprises at least one of galacto-oligosaccharide, fructo-oligosaccharide, inulin and polydextrose;
optionally, the additive amount of the auxiliary materials accounts for 1.0-50.0 wt% of the total mass of the composite probiotic composition.
Optionally, the preparation method of the composite probiotic composition comprises the step of mixing raw materials containing various strains;
optionally, the method further comprises the step of adding auxiliary materials after mixing the raw materials containing the strains.
Optionally, the complex probiotic composition further has the use of any one of the following (a) to (f):
(a) use in the preparation of a food or a medicament for reducing visceral fat
(b) The use in the preparation of a food or medicament for reducing the cholesterol level in blood;
(c) use in the preparation of a food or medicament for reducing the low density lipoprotein content in blood;
(d) the application in preparing food or medicine for increasing the content of high-density lipoprotein in blood;
(e) the use in the preparation of a food or a medicament for inhibiting the increase of the content of D-lactic acid in blood or reducing the content of D-lactic acid in blood;
(f) use in the manufacture of a food or medicament for reducing the level of diamine oxidase in blood;
(g) the application in the preparation of direct vat set starter.
Optionally, the food comprises general food, health food and adjuvant treatment type food.
Optionally, the food comprises a food prepared by fermenting the composite probiotic composition as a leavening agent.
Optionally, the food product comprises a soy product, a dairy product, or a fruit and vegetable product.
The technical scheme of the invention has the following advantages:
1. the invention provides an application of a composite probiotic composition in preparing food or medicines for preventing, relieving, adjunctively treating or treating hyperlipemia, wherein the composite probiotic composition comprises the following components in parts by weight: lactobacillus casei Zhang (Lactobacillus casei Zhang) with the preservation number of CGMCC No. 5469; bifidobacterium animalis subsp. lactis V9(Bifidobacterium animalis subsp. lactis V9) with the preservation number of CGMCC No. 5470; lactobacillus plantarum P-8(Lactobacillus plantarum P-8), with the preservation number of CGMCC No. 6312; lactobacillus rhamnosus Probio-M9(Lactobacillus rhamnous Probio-M9) with the preservation number of CGMCC No. 18639; and Bifidobacterium lactis Probio-M8(Bifidobacterium lactis Probio-M8) with the preservation number of CGMCC number 18610; the composite probiotic composition has the effects of preventing, relieving, assisting in treating or treating hyperlipidemia, and has a great application prospect in preparing products for relieving and treating hyperlipidemia and other diseases.
2. The invention provides application of a composite probiotic composition in preparing food or medicine for preventing, relieving, adjunctively treating or treating hyperlipidemia, wherein the total viable count of the probiotic composition is not less than 3.0 x 10 10 cfu/g, viable count of each strain is not less than 6.0 × 10 9 cfu/g; the composite probiotic composition can remarkably improve the related symptoms of hyperlipidemia by regulating intestinal flora of human bodies.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the embodiments or the prior art descriptions will be briefly described below, and it is obvious that the drawings in the following description are some embodiments of the present invention, and other drawings can be obtained by those skilled in the art without creative efforts.
FIG. 1 is a graph showing the change in LDL-C levels in subjects before and after intervention in a probiotic group and a placebo group in an experimental example of the present invention; the values in parentheses in the abscissa are the values corresponding to the ordinate thereof.
FIG. 2 is a graph showing the change in TC content in subjects before and after intervention in the probiotic and placebo groups in the experimental examples of the present invention; the values in parentheses in the abscissa are the values corresponding to the ordinate thereof.
FIG. 3 is a graph showing the change in HDL-C levels in subjects before and after intervention in the probiotic and placebo groups in the experimental examples of the present invention; the values in parentheses in the abscissa are the values corresponding to the ordinate thereof.
FIG. 4 shows the D-lactic acid content change in subjects before and after intervention in the probiotic group and the placebo group in the experimental examples of the present invention; the values in parentheses in the abscissa are the values corresponding to the ordinate thereof.
FIG. 5 shows the change of diamine oxidase content in subjects before and after intervention in the probiotic group and the placebo group in the experimental examples of the present invention; the values in parentheses in the abscissa are the values corresponding to the ordinate thereof.
FIG. 6 shows visceral fat content changes in subjects before and after intervention in the probiotic group and the placebo group in the experimental examples of the present invention; the values in parentheses in the abscissa are the values corresponding to the ordinate thereof.
Detailed Description
The following examples are provided to further understand the present invention, not to limit the scope of the present invention, but to provide the best mode, not to limit the content and the protection scope of the present invention, and any product similar or similar to the present invention, which is obtained by combining the present invention with other prior art features, falls within the protection scope of the present invention.
The examples do not indicate specific experimental procedures or conditions, and can be performed according to the procedures or conditions of the conventional experimental procedures described in the literature in the field. The reagents or instruments used are not indicated by manufacturers, and are all conventional reagent products which can be obtained commercially.
Lactobacillus casei zhang is 1 strain of probiotics with various probiotic functions separated from natural fermented mare milk in inner Mongolia grassland in 2002, is the probiotic bacteria for completing whole genome sequencing of the 1 st strain in China, has been preserved in 2011 at 11/18 days, is preserved in the common microorganism center of China Committee for culture Collection of microorganisms, and has the preservation address No. 3 of Xilu 1 of Beijing & on the sunward district, the preservation numbers are: CGMCC No. 5469. The experimental research finds that: and L, casein Zhang intervention can accelerate fatty acid oxidation so as to play a role in reducing blood fat.
Bifidobacterium animalis subsp.lactis V9(Bifidobacterium animalis subsp. lactis) was deposited at the general microbiological center of China Committee for culture Collection of microorganisms at 18.11.2011 at the location of No. 3, Sai Lu No.1, North Cheng Yang district, Beijing, with the deposit numbers: CGMCC No. 5470. The genomics research finds that the strain has extremely low probability of recombination and mutation and stable heredity.
Lactobacillus plantarum P-8(Lactobacillus plantarum P-8) is 1 Lactobacillus plantarum with superior probiotic properties isolated in 2005 from the natural fermented yoghurt sample of the Tamarindus domestic in Wulat, Bayan, Tengla, inner Mongolia. Has been preserved in China general microbiological culture Collection center at 28.06.2012, the preservation address of No. 3 Xilu No.1, North Cheng of the south Kogyo area, Beijing city, with the preservation numbers: CGMCC No. 6312.
Lactobacillus rhamnosus Probio-M9(Lactobacillus rhamnous Probio-M9) was isolated from breast milk of healthy women in 2017. Has been preserved in China general microbiological culture Collection center at the general microbiological culture Collection center of China general microbiological culture Collection center at 2019, No. 3 of Xilu No.1 of Beijing, Chaoyang, with the preservation numbers: CGMCC No. 18639.
Bifidobacterium lactis Probio-M8(Bifidobacterium lactis Probio-M8) was isolated from breast milk of healthy women in 2017. Has been preserved in China general microbiological culture Collection center in the general microbiological culture Collection center of China general microbiological culture Collection center at 20 days 9 months 2019, the preservation address is No. 3 Xilu No.1 on the North Chen of the Chaoyang district in Beijing, and the preservation numbers are: CGMCC No. 18610.
In the composite probiotic powder, the total viable count of Lactobacillus casei Zhang, Bifidobacterium animalis subspecies lactis V9, Lactobacillus plantarum P-8, Lactobacillus rhamnosus Probio-M9 and Bifidobacterium lactis Probio-M8 is more than or equal to 3.0 × 10 10 cfu/g。
The preparation method of the probiotic powder comprises the following steps:
1) activation of strains: respectively inoculating strains (Lactobacillus casei Zhang, Bifidobacterium animalis subsp. lactis V9, Lactobacillus plantarum P-8, Lactobacillus rhamnosus Probio-M9 and Bifidobacterium lactis Probio-M8) which are frozen and preserved at the temperature of-40 ℃ into corresponding liquid culture media sterilized at the temperature of 121 ℃ for 15min, carrying out anaerobic culture at the temperature of 37 ℃ for 18-24h, and carrying out subculture for 1-2 times to obtain activated strains; the liquid culture medium corresponding to lactobacillus (Lactobacillus casei Zhang, Lactobacillus plantarum P-8, Lactobacillus rhamnosus Probio-M9) is MRS liquid culture medium, and the liquid culture medium corresponding to Bifidobacterium (Bifidobacterium animalis subsp. lactis V9 and Bifidobacterium lactis Probio-M8) is TPY liquid culture medium.
2) Preparation of an optimized culture medium:
preparing the components of the optimized culture medium according to a proportion, uniformly mixing, adjusting the pH value to 6.5,121 ℃, and sterilizing for 15 min;
the optimized culture medium for bifidobacterium comprises the following components: 12.0Kg of lactose, 7.0Kg of beef extract, 7.0Kg of yeast powder, 12.0Kg of casein peptone, 7.0Kg of soybean peptone and KH 2 PO 4 4.0Kg，K 2 HPO 4 1.0Kg， MgSO 4 0.05Kg, tween-800.15 Kg, 0.7Kg of L-cysteine hydrochloride, 1.2Kg of calcium carbonate, and 1000L of distilled water.
The lactobacillus optimized culture medium comprises the following components: 23.5Kg of sucrose, 12.0Kg of lactose, 15.0Kg of soyabean peptone, 5.0Kg of yeast powder, 12Kg of yeast peptone and Na 2 HPO 3 21.0Kg, 2.0Kg of citric acid, MgSO4 & 7H 2 O 0.6Kg，MnSO 4 5H 2 0.3Kg of O, 801.0 Kg of Tween-L, 0.3Kg of L-cysteine hydrochloride and 1000L of distilled water.
3) Preparing a seed solution:
inoculating each strain activated in the step 1) into the optimized culture medium prepared in the step 2), and stopping anaerobic culture at 37 ℃ until the pH value is 4.5-4.8;
4) inoculation and fermentation:
respectively inoculating the seed liquid obtained in the step 3) into the optimized culture medium prepared in the step 2) according to 1 per thousand correspondingly, and fermenting for 18 hours under controlled fermentation conditions;
the fermentation conditions are controlled as follows: culturing at 30 deg.C before fermentation, and naturally fermenting until pH is 5.0; then adjusting the fermentation temperature to 37 ℃ for constant-temperature culture, controlling the pH value to keep 6.0, and keeping the total fermentation time of anaerobic fermentation to 18 h.
The pH is controlled by feeding a neutralizing agent, wherein the neutralizing agent is NaOH.
Wherein the anaerobic condition is achieved by passing nitrogen every two hours.
5) Terminating the fermentation
Stopping fermentation when the bacteria produce acid, obtaining high-density fermentation liquor of each bacterial strain, wherein the viable count of the fermentation liquor reaches 2 multiplied by 10 10 More than cfu/ml.
Wherein, whether the acid production is stopped or not can be judged according to the condition that the pH value is not reduced any more and the feeding of the neutralizing agent is stopped.
6) Freeze drying
a. And (3) thallus concentration: carrying out centrifugal concentration on the high-density fermentation liquor by 12000g to obtain thalli;
b. adding a protective agent: adding protective agent solution with 3-8 times of volume times into the thallus concentrated solution; the protectant solution consisted of: 10-15Kg of skim milk, 8-12Kg of lactose, 1-2Kg of vitamin C, 1-2Kg of sodium glutamate and 1000L of distilled water.
c. And (3) drying: freeze drying the bacterial suspension after adding the protective agent to obtain freeze dried bacterial powder of each strain, wherein the total number of viable bacteria in each strain reaches 6.0 multiplied by 10 11 cfu/g or more.
Example 1
A composite probiotic composition comprises the following components in percentage by weight: 0.01g of lactobacillus casei Zhang powder, 0.01g of bifidobacterium animalis subsp lactis V9 powder, 0.01g of lactobacillus plantarum P-8 powder, 0.01g of lactobacillus rhamnosus Probio-M9 powder, 0.01g of bifidobacterium lactis Probio-M8 powder and 0.6mg of auxiliary material maltodextrin.
The preparation method of the composite probiotic composition comprises the steps of weighing freeze-dried powder of each strain according to a formula, uniformly mixing, adding auxiliary materials, and uniformly mixing.
Example 2
A composite probiotic composition comprises the following components in percentage by weight: 0.01g of lactobacillus casei Zhang powder, 0.01g of bifidobacterium animalis subsp lactis V9 powder, 0.01g of lactobacillus plantarum P-8 powder, 0.01g of lactobacillus rhamnosus Probio-M9 powder, 0.01g of bifidobacterium lactis Probio-M8 powder and 50mg of inulin serving as an auxiliary material.
The preparation method of the composite probiotic composition comprises the steps of weighing freeze-dried powder of each strain according to a formula, uniformly mixing, adding auxiliary materials, and uniformly mixing.
Example 3
A composite probiotic composition comprises the following components in percentage by weight: 1g of lactobacillus casei Zhang bacteria powder, 1g of bifidobacterium animalis subsp lactis V9 bacteria powder, 1g of lactobacillus plantarum P-8 bacteria powder, 1g of lactobacillus rhamnosus Probio-M9 bacteria powder, 1g of bifidobacterium lactis Probio-M8 bacteria powder and 1.5g of auxiliary material polydextrose.
The preparation method of the composite probiotic composition comprises the steps of weighing freeze-dried powder of each strain according to a formula, uniformly mixing, adding auxiliary materials, and uniformly mixing.
Experimental example (a) experimental design:
the test population: the subject should be 18-70 years old, male and female unlimited, meet any one of the following or satisfy both: triglyceride is more than or equal to 1.8mmol/L, and total cholesterol is more than or equal to 5.7 mmol/L. Has not been used and treatment with lipid lowering drugs has not been planned for a short period of time.
And (3) inclusion standard: subjects were eligible for inclusion in the study only if they met all of the following criteria.
1. Male or female, and the age is 18-70 years old;
BMI (body Mass Indx) at 24kg/m 2 -30kg/m 2 To (c) to (d);
3. the waistline of the male is more than or equal to 90cm, and the waistline of the female is more than or equal to 85 cm;
4. antibiotics are not used in 1 month before the group is entered;
5. no history of chronic gastrointestinal disorders;
6. agree to participate in the study and sign a written informed consent;
7. the new discovered or existing hyperlipemia patients can have no other complications and are not treated by lipid-lowering medicines;
exclusion criteria: the subject is not eligible for inclusion if either:
1. women who are scheduled to be pregnant during pregnancy, lactation or within 6 months;
2. patients with hepatic insufficiency: glutamic-pyruvic transaminase and glutamic-oxalacetic transaminase are more than or equal to 2 times of the normal value; renal insufficiency: the filtration rate of glomerulus is less than or equal to 90ml/min/1.72m 2 ；
4. Hypertension, and the blood pressure is still higher than 160/100mmHg by using more than 2 antihypertensive drugs;
5. patients with cardiac insufficiency;
6. those with anemia or other blood disorders;
7. patients with diabetes;
8. those with lactic acid bacteria and products thereof having a history of allergy or high-sensitivity constitution;
9. other drug investigators were accepted within 3 months prior to screening;
sample size: in total 200 cases. High group of simple triglyceride 100 cases; the group with high total cholesterol is 100.
The main curative effect indexes are as follows: treating three-month-end blood triglyceride and blood total cholesterol level reaching standards (triglyceride is less than 1.8mmol/L, total cholesterol is less than 5.7 mmol/L);
(II) research method
1. Enteric probiotic formulations and placebo instructions
The study used a double-blind approach, where the probiotic group and the placebo group were given the same diet and exercise instructions, and the probiotic group was given 2g of the composite probiotic composition of example 1 per day (total viable count not less than 300 hundred million cfu/d), and the placebo group was given 2 g/day of a placebo (maltodextrin) with identical package, color, odor and probiotic, and three months of follow-up observation was performed and blood and stool samples were collected at the beginning (0d) and end (90d) of the trial. (randomized double-blind, non-interventional, parallel-control clinical study with patients randomized 1: 1 assignment to placebo and probiotic groups.)
2. Application method of intestinal probiotic preparation
It can be administered orally directly or with warm water (below 40 deg.C) 1 time a day and 1 bag 1 time.
3. Course of treatment
The treatment period is 3 months in total, and the follow-up observation period is 3 months.
4. Combined use of medicine
Other combinations of drugs may be used under the direction of the investigator during the course of treatment if necessary for the safety and health of the subject, provided that the administration of the drug does not have any effect on the efficacy assessment of the study drug. All combinations and dosages, dose adjustments, and start and stop times of administration of the combinations were recorded on CRF.
5. Forbidden medicine
The following drugs should not be used during the treatment study: antibiotics, other preparations of the intestinal flora or drugs which may interfere with the intestinal flora
6. Standard treatment for stopping drug
(1) ALT or AST 2 times greater than upper normal limit:
(2) the SCR is larger than the upper limit of a normal value;
(3) white blood cell count<3.0×10 9 /L；
(4) Platelet count<80×10 9 /L；
(5) Absolute value of neutrophil<1.5×10 9 /L。
In any case, the medicine should be stopped for 7 days, and the indexes should be reviewed. If the drug use standard is not met, the research is stopped; if the normal state is recovered, the medicine is continued to be taken. If the condition of meeting the drug stopping standard occurs twice in the research process, the research is stopped.
(III) test methods and results
1. The study used a double blind approach to randomly distribute 70 subjects who were finally enrolled 1: 1 to a placebo group (35 persons) and a probiotic group (35 persons), both groups given the same diet and exercise guidance, the probiotic group taking 2g of the complex probiotic composition per day (300 hundred million cfu/d, the placebo group given 2 g/day of a placebo (maltodextrin) of identical package, color, odor and probiotic, three months of follow-up observation and collecting blood and stool samples at the beginning (0d) and end (90d) of the trial, combined observations of clinical effects on hyperlipidemic patients and changes in fat factors during glycolipid metabolism.
2. Index testing
LDL-C content, TC content in blood, HDL-C content, D-lactic acid content, diamine oxidase content and visceral fat content changes in subjects of the initial (0D) and three-month-end (90D) probiotic and placebo groups were examined. LDL-C (Normal value)<3.37mmol/L), TC (Normal value)<5.18mmol/L), HDL-C (Normal value)>1.04mmol/L), D-lactic acid (Normal value)<15 mmol/L), diamine oxidase (normal value)<10mmol/L), visceral fat (normal value)<100cm 2 )。
Blood was collected from each group of subjects at month 0 (no drug administration on day 0) and 3 months after treatment (day 90) for the following indices:
LDL-C content: the test kit consists of
Figure RE-RE-GDA0003728295660000121
Model E-BC-K221-M is provided. A detection method for quantitatively determining LDL-C by a combination masking method. The method adopts a liquid double reagent which consists of a reagent 1 and a reagent 2 which are respectively placed, wherein the reagent 1 contains divalent metal chloride calcium chloride, the concentration range of the divalent metal chloride calcium chloride is 0.4g/L-0.5g/L, an LDL-C monoclonal antibody is an apolipoprotein B monoclonal antibody, the concentration range of the LDL-C monoclonal antibody is 50ml/L-150ml/L, and a quantitative enzyme reagent; the reagent 2 contains a surfactant, a color developing agent, a preservative, an anti-interference substance and a reaction promoter. The method has good color development characteristic, high accuracy and stable reagent components.
Content of TC in blood: a kit detection method is used, and is provided by Beijing Rayleigh biotechnology limited company and named as a Total Cholesterol (TC) detection kit (COD-PAP single reagent microplate method);
HDL-C content: a kit test method was used, supplied by eliekan under the name high density lipoprotein cholesterol (HDL-C) test kit (direct method), cat # L7003;
d-lactic acid content: a detection method using a kit, which is provided by Beijing Rayleigh biotechnology Co., Ltd and is named as a D-lactic acid detection kit (lactate dehydrogenase colorimetric method);
diamine oxidase content: using a kit detection method, provided by Beijing Soilebao science and technology Co., Ltd, and named as a diamine oxidase activity detection kit with a goods number BC 1285;
visceral fat content: detection was accomplished using dual energy X-ray absorptiometry.
3. Test results
(1) As can be seen from fig. 1, the probiotic group significantly reduced the LDL-C level in the blood of hyperlipidemic patients (23/35-reduction, P ═ 0.0086) compared to the placebo group.
(2) As can be seen from fig. 2, probiotics also significantly reduced the level of TC in the blood (24/35 human reduction, P ═ 0.0017), without significant change with placebo intervention (P ═ 0.10).
(3) As can be seen from fig. 3, probiotic intervention significantly increased HDL-C levels in subjects (15/35 increased, P ═ 0.023), while the HDL-C levels in volunteers were significantly decreased after placebo intervention (26/35 decreased, P ═ 0.0016).
(4) As can be seen from fig. 4, compared to placebo, the probiotics significantly inhibited the increase of D-lactic acid content in the blood of the subjects, and also significantly reduced D-lactic acid in the blood of some subjects (P <0.0001), and the higher the initial content, the larger the reduction (r is 0.93, P < 0.0001).
(5) As can be seen from fig. 5, although the diamine oxidase in the blood of most of the subjects (67/70 people) was in the normal range, the diamine oxidase in the blood of the placebo volunteers was significantly increased (P0.0014), while the probiotic bacteria were able to significantly decrease the diamine oxidase in the volunteers (P0.0023).
(6) As can be seen from fig. 6, visceral fat decreased significantly (P <0.05) in both the probiotic group and the placebo group, but the decrease was greater in the probiotic group compared to the placebo group. Indicating that the probiotic group can significantly improve the symptoms related to hyperlipidemia.
In conclusion, the compound probiotic composition has good safety when being taken, can be effectively used for treating patients with hyperlipidemia, and further shows that the compound probiotic composition has a certain improvement effect on the symptoms of patients with hyperlipidemia.
It should be understood that the above examples are only for clarity of illustration and are not intended to limit the embodiments. Other variations and modifications will be apparent to persons skilled in the art in light of the above description. And are neither required nor exhaustive of all embodiments. And obvious variations or modifications therefrom are within the scope of the invention.

Claims (9)

1. Use of a complex probiotic composition in the preparation of a food or medicament for the prevention, alleviation, co-treatment or treatment of hyperlipidaemia, wherein said complex probiotic composition comprises:
lactobacillus casei Zhang (Lactobacillus casei Zhang) with the preservation number of CGMCC No. 5469;
bifidobacterium animalis subsp. lactis V9(Bifidobacterium animalis subsp. lactis V9) with the preservation number of CGMCC No. 5470;
lactobacillus plantarum P-8(Lactobacillus plantarum P-8), with the preservation number of CGMCC No. 6312;
lactobacillus rhamnosus Probio-M9(Lactobacillus rhamnous Probio-M9) with the preservation number of CGMCC No. 18639; and
bifidobacterium lactis Probio-M8(Bifidobacterium lactis Probio-M8) with the collection number of CGMCC No. 18610.
2. Use according to claim 1, characterized in that the total viable count of the composite probiotic composition is not less than 3.0 x 10 10 cfu/g, viable count of each strain is not less than 6.0 × 10 9 cfu/g。
3. The use according to claim 1 or 2, wherein the raw material of each strain comprises any one of a culture, a fermentation product or a lyophilized powder of the strain;
optionally, the raw material of each strain is freeze-dried powder of the strain.
4. The use according to any one of claims 1 to 3, further comprising an adjuvant;
optionally, the auxiliary material is prebiotics or dietary fibers;
optionally, the auxiliary material comprises at least one of galacto-oligosaccharide, fructo-oligosaccharide, inulin and polydextrose;
optionally, the additive amount of the auxiliary materials accounts for 1.0-50.0 wt% of the total mass of the composite probiotic composition.
5. The use according to any one of claims 1 to 4, characterized in that it also comprises a process for the preparation of a complex probiotic composition, comprising the steps of mixing the raw materials containing the strains;
optionally, the method further comprises the step of adding auxiliary materials after mixing the raw materials containing the strains.
6. The use according to any one of claims 1 to 5, characterized in that the complex probiotic composition also has the use according to any one of the following (a) to (f):
(a) use in the preparation of a food or a medicament for reducing visceral fat
(b) The use in the preparation of a food or medicament for reducing the cholesterol level in blood;
(c) use in the preparation of a food or medicament for reducing the low density lipoprotein content in blood;
(d) the application in preparing food or medicine for increasing the content of high-density lipoprotein in blood;
(e) the use in the preparation of a food or a medicament for inhibiting the increase of the content of D-lactic acid in blood or reducing the content of D-lactic acid in blood;
(f) use in the manufacture of a food or medicament for reducing the level of diamine oxidase in blood;
(g) the application in the preparation of direct vat set starter.
7. Use according to any one of claims 1 to 6, wherein the food products include general foods, health foods and therapeutic-aid foods.
8. Use according to any one of claims 1 to 7, characterized in that the food product comprises a food product prepared by fermentation of the complex probiotic composition as a starter.
9. Use according to claim 8, wherein the food product comprises a soy product, a dairy product or a fruit and vegetable product.
CN202210301358.2A 2022-03-24 2022-03-24 Composite probiotic composition with obvious effect of improving hyperlipidemia Pending CN114848684A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210301358.2A CN114848684A (en) 2022-03-24 2022-03-24 Composite probiotic composition with obvious effect of improving hyperlipidemia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210301358.2A CN114848684A (en) 2022-03-24 2022-03-24 Composite probiotic composition with obvious effect of improving hyperlipidemia

Publications (1)

Publication Number Publication Date
CN114848684A true CN114848684A (en) 2022-08-05

Family

ID=82628620

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210301358.2A Pending CN114848684A (en) 2022-03-24 2022-03-24 Composite probiotic composition with obvious effect of improving hyperlipidemia

Country Status (1)

Country Link
CN (1) CN114848684A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115956678A (en) * 2022-12-01 2023-04-14 中南大学湘雅二医院 Composite probiotic dietary fiber composition and application thereof
CN116731905A (en) * 2022-11-30 2023-09-12 越用越好(上海)生物科技有限公司 Probiotic composition and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108157973A (en) * 2017-12-14 2018-06-15 上海交通大学医学院附属瑞金医院 The probiotic composition and its preparation of a kind of beneficial glycolipid metabolism function and application
CN109223832A (en) * 2017-07-10 2019-01-18 上海立龙生物科技有限公司 A kind of probiotic composition preventing and treating hyperlipidemia
CN109628358A (en) * 2019-02-20 2019-04-16 无限极（中国）有限公司 A kind of compound probiotic and its application
CN111213885A (en) * 2020-01-20 2020-06-02 齐海心 Probiotic composition with blood fat regulating effect and preparation method and application thereof
CN113832058A (en) * 2021-09-23 2021-12-24 微康益生菌(苏州)股份有限公司 Application of bifidobacterium lactis BLA80 in preparation of medicines or foods for reducing blood fat and regulating intestinal flora

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109223832A (en) * 2017-07-10 2019-01-18 上海立龙生物科技有限公司 A kind of probiotic composition preventing and treating hyperlipidemia
CN108157973A (en) * 2017-12-14 2018-06-15 上海交通大学医学院附属瑞金医院 The probiotic composition and its preparation of a kind of beneficial glycolipid metabolism function and application
CN109628358A (en) * 2019-02-20 2019-04-16 无限极（中国）有限公司 A kind of compound probiotic and its application
CN111213885A (en) * 2020-01-20 2020-06-02 齐海心 Probiotic composition with blood fat regulating effect and preparation method and application thereof
CN113832058A (en) * 2021-09-23 2021-12-24 微康益生菌(苏州)股份有限公司 Application of bifidobacterium lactis BLA80 in preparation of medicines or foods for reducing blood fat and regulating intestinal flora

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
张泽生;王俊辉;李健;赵春晓;: "四株益生菌对高脂血症仓鼠降血脂作用的研究", 食品工业科技, no. 12, 15 June 2012 (2012-06-15) *
郭俊霞等: "益生菌改善代谢综合症研究进展", 食品安全质量检测血报, vol. 5, no. 6, 30 June 2014 (2014-06-30), pages 4 *
陈霞等: "益生菌体外降解胆固醇的研究进展", 工业微生物, vol. 50, no. 4, 31 August 2020 (2020-08-31), pages 52 *
黄文丽等: "益生菌降血脂作用及机制研究进展", 工业微生物, vol. 48, no. 4, 22 August 2018 (2018-08-22), pages 1 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116731905A (en) * 2022-11-30 2023-09-12 越用越好(上海)生物科技有限公司 Probiotic composition and application thereof
CN116731905B (en) * 2022-11-30 2024-02-09 越用越好(上海)生物科技有限公司 Probiotic composition and application thereof
CN115956678A (en) * 2022-12-01 2023-04-14 中南大学湘雅二医院 Composite probiotic dietary fiber composition and application thereof

Similar Documents

Publication Publication Date Title
CN110150669B (en) Probiotic composition suitable for diabetic patients and application thereof
CN114848684A (en) Composite probiotic composition with obvious effect of improving hyperlipidemia
CN111213885A (en) Probiotic composition with blood fat regulating effect and preparation method and application thereof
CN116555076B (en) Bifidobacterium longum subspecies longum MY1 and application thereof in preparation of food and medicine for relaxing bowels and protecting intestines
WO2008012947A1 (en) Anti-fatty liver agent
CN114717147A (en) Metazoan prepared from Lactobacillus rhamnosus and used for relieving fatty liver and obesity, and application thereof
CN112899190B (en) Lactobacillus paracasei LPC48 with preventing and/or improving functions on gout and application thereof
CN110959867A (en) Composite probiotic microcapsule powder for emulsification and preparation method and application thereof
CN114432346A (en) Composite probiotic composition for treating hyperuricemia and gout and preparation method and application thereof
CN115927045B (en) Lactobacillus salivarius 069 with cholesterol reducing and liver injury relieving functions caused by hyperlipidemia and application thereof
CN115281345A (en) Application of composite probiotic composition in combination with dimethylguanidine to treatment of type II diabetes
CN113755370B (en) Application of lactobacillus acidophilus LA85 in preparation of hypolipidemic drugs or health-care foods
CN109207389B (en) Thrombolytic lipid-lowering probiotic compound bacteria traditional Chinese medicine oral liquid and preparation method thereof
EP2407170B1 (en) Prevention and treatment of obesity and metabolic diseases induced by obesity using microorganisms
CN117004503B (en) Saliva combined lactobacillus MB1 and application thereof in preparation of food and medicine for assisting sleep and regulating intestines and stomach
CN111228316B (en) Composite probiotics for improving diabetes
JP6862464B2 (en) Faecalibacterium longum and its use
CN114686405B (en) Bifidobacterium bifidum with functions of reducing fat, relieving hyperglycemia and regulating intestinal immunity and application thereof
CN115466689B (en) Probiotic composition for preventing and/or treating metabolic diseases and application thereof
CN116445356A (en) Bifidobacterium animalis subspecies BA67 for regulating intestinal flora and enhancing immunity and application thereof
CN116024129A (en) Lactobacillus crispatus capable of co-aggregating with helicobacter pylori and application thereof
AU2019257482B2 (en) Composition for promoting glucolipid metabolism, and preparation and application thereof
CN112961808A (en) Lipid-lowering and weight-losing bifidobacterium lactis preparation and preparation method thereof
CN110839693A (en) Application of parabacteroides gibsonii in preventing or treating obesity or related diseases
CN110062806B (en) Corynebacterium faecalis (Anaerothrips caccae) and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination